Fisher & Paykel Healthcare Corporation Limited · NZX:FPH

Fisher & Paykel Healthcare — Investor Day (September 2018)

114 slides from Fisher & Paykel Healthcare's investor day presentation, Sep 21, 2018

  1. Slide 1: Investor Day Presentation in Mexico and the United States

    Stock Exchange Announcement STOCK EXCHANGE LISTINGS: NEW ZEALAND (FPH), AUSTRALIA (FPH) For personal use only Fisher & Paykel Healthcare Investor Day Presentation in Mexico and the United States Auckland, New Zealand, 21 September 2018 - Fisher & Paykel Healthcare Corporation Limited (NZX:FPH, ASX:F

  2. Slide 2: US and Mexico Investor Day 2018

    US and Mexico “% Investor Day 2018 21 September 2018 Fisher & Paykel HEALTHCARE

  3. Slide 3: Morning Agenda

    Morning Agenda 8:30am 8:30am 8:45am 9:30am 10:30am 1:00am 11:30am 12:30pm- 1:30pm Welcome Marcus Driller Manufacturing Overview Andrew Somervell Mexico: Delivering Sustainable Growth Raul Sanchez Malena Ortiz Tour of Spence Manufacturing Facility Raul Sanchez Complete facility tour and board coach T

  4. Slide 4: Our approach to Manufacturing

    Our approach te ian | > ; Manufacturing _ | 4 y _ eo Dr Andrew Somervell = VP - Products & Technol Fisher & Paykel HEALTHCARE

  5. Slide 5: For personal use only

    4 For personal use only • • • − − − −

  6. Slide 6: For personal use only

    5 For personal use only • • − − − − − − − −

  7. Slide 7: For personal use only

    6 For personal use only • • • − − − • •

  8. Slide 8: Questions?

    Questions? Dr Andrew Somervell \ VP - Products & Technology 3 a Fisher & Paykel HEALTHCARE

  9. Slide 9: Mexico: Delivering Sustainable Growth

    For personal use only Mexico: Delivering Sustainable Growth Raul Sanchez General Director Mexico Operations Malena Ortiz Finance & Group Services Director HEALTHCARE

  10. Slide 10: For personal use only

    For personal use only • • • • • Source: Tijuana Medical Cluster/Instituto Nacional de Estadística y Geografía (INEGI) 9

  11. Slide 11: Medical Device Industry in Tijuana

    Medical Device Industry in Tijuana >2.4 million employees in the Maquiladora Industry in Mexico in 5,000+ companies. >38,000 people 44+ Medical Device manufacturing plants in Tijuana. Hospitalization 02 |___ 0! Ophthalmology and Surgery ia GBD B8nypro SURGICAL it Yeats 02 Respiratory smiths MERTEDIC

  12. Slide 12: Our Journey

    Our Journey SE99 999990 Lease agreement signed and fit-out starts. f AAA Fit-out completed. First full face mask shipped. First breathing circuit shipped. First shipments to Europe. Received Japan accreditation. Started HC405 mask production. Second chamber line installed. Commenced production of Ev

  13. Slide 13: La Encantada Campus, Tijuana, Mexico

    La Encantada Campus, Tijuana, Mexico os Fisheré.Paykel HEALTHCARE

  14. Slide 14: Melville Building, La Encantada Campus

    Melville Building, La Encantada Campus 7 the Z, fag O9FeSS™ Building Size m2 : 22,888 eS z < te Fisheré.Paykel HEALTHCARE

  15. Slide 15: Our People

    Our People NUMBER OF EMPLOYEES IN MEXICO 1000 7 900 800 700 600 or 826 667 507 500 469 400 33g 38 300 243 200 100 ° FYI FYI2. FYI3. ~FYI4. -FYIS) «-FYI6. «FYIT.—s FYB 44% Male 56% Female 1,000+ associates 64% Direct 36% Indirect Fisher & Paykel HEALTHCARE u

  16. Slide 16: For personal use only

    For personal use only *Source: Ruiz-Morales y Asociados Firm 15

  17. Slide 17: Continuing Education

    Continuing Education We believe that Educational Program: education is not an 07 Master's Degree opportunity but an investment in our future. O9 Bachelor’s Degree 84 High School Graduates: O2 master’s Degree citys oO cA sites UNIVERSIDAD O1 Bachelor’s Degree 18 High School MIT ue, GliRabas ONBEEES F

  18. Slide 18: Mexico Objectives

    Mexico Objectives LICENSE TO SUPPLY CHAIN PROCESS BUSINESS OPERATIONAL OPERATE INTEGRATION FOCUSED INNOVATION EXCELLENCE Fisher & Paykel HEALTHCARE

  19. Slide 19: Operational Excellence

    Operational Excellence Fisher’ Paylel Results Enterprise Alignment SA Continuous Improvement People GUIDING PRINCIPLES SUPPORTING CONCEPTS Cultural Enablers l YS Bw? Creating long-term and sustainable solutions rather than leaving temporary fixes in place. Fisher & Paykel HEALTHCARE

  20. Slide 20: People Initiatives

    People Initiatives 56+ Kaizen Events 38+ Lean | Six Sigma Certifications Workplace Optimization After Fisher & Paykel

  21. Slide 21: Employee Health & Safety

    20 Employee Health & Safety We know that tomorrow matters as much as today. We are one connected family and what makes us family is our commitment to work well and live better. @) Process | 0 Plant 4 Oy Fisher & Paykel HEALTHCARE

  22. Slide 22: Workstation Ergonomics

    Workstation Ergonomics After HEALTHCARE

  23. Slide 23: Quality

    Quality Fisher & Paykel HEALTHCARE

  24. Slide 24: For personal use only

    oO =) a THA s 0D Sse Y) MS O 12) Cc D O LL oO

  25. Slide 25: For personal use only

    24 For personal use only 17

  26. Slide 26: Questions?

    For personal use only Questions? Raul Sanchez General Director Mexico Operations Malena Ortiz Finance & Group Services Director Fisher & Paykel HEALTHCARE

  27. Slide 27: Afternoon Agenda

    Afternoon Agenda 1:30pm Sustainable Profitable Growth Lewis Gradon Managing Director & CEO 1:40pm Global Sales Approach Paul Shearer Senior VP - Sales & Marketing 2:00pm North American Overview Justin Callahan President - US Operations 2:25pm US Hospital Overview Steve Lacke VP Sales & Marketing - U

  28. Slide 28: Our Aspiration: Sustainably Doubling Revenue

    OUR ASPIRATION: ra) ® A) @ Sustainably RESPIRATORY CPAP HOSPITAL HOME SURGICAL HUMIDIFICATION THERAPY/OSA RESPIRATORY RESPIRATORY TECHNOLOGIES D fe) U B LI N G SUPPORT SUPPORT our constant currency revenue every 5-6 years. } Fon) SHORT-TERM MEDIUM-TERM LONGER-TERM “CONSTANT CURRENCY Fisher & Paykel

  29. Slide 29: Global Sales Approach

    v Global Sales Approach Paul Shearer Senior VP - Sales & Marketing Fisher & Paykel HEALTHCARE

  30. Slide 30: Strong Global Presence

    29 Strong Global Presence REVENUE BY REGION Fisheré.Paykel - "12 MONTHS TO 31 MARCH 2018 HEALTHCARE

  31. Slide 31: Multi-Channel Distribution Model

    Multi-Channel Distribution Model DIRECT SALES OPERATION Control of sales process Sales force focus Accelerates sales Fisher & Paykel HEALTHCARE

  32. Slide 32: For personal use only

    31 For personal use only • • • • • − − − − − − − −

  33. Slide 33: Clinical Change Process

    Clinical Change Process C PRODUCT DEVELOPMENT FEEDBACK D) f YY TRUSTED ADVISOR Process: © nce © ee © }$ed6 nowledge LONG COMPLEX SALES CYCLE ] use only na For perso Fisheré.Paykel 32 HEALTHCARE

  34. Slide 34: For personal use only

    33 For personal use only • • • − − − − − −

  35. Slide 35: Questions?

    v Questions? Paul Shearer Senior VP - Sales & Marketing Fisher & Paykel ba HEALTHCARE

  36. Slide 36: North America Overview

    North America Overvi Justin Callahan, President Fisher & Paykel Healthcare Inc.

  37. Slide 37: Overview of our North American Business

    Overview of our North American Business NORTH AMERICAN REVENUE NORTH AMERICAN EMPLOYEES US$M 350 350 8,000+ direct 300 300 customers 250 250 200 200 150 150 250,000 square 100 100 feet of distribution facilities 50 50 ie) ie) e S ae @ FP PS PS F925 300+ employees Fisheré.Paykel 36 HEALTHCARE

  38. Slide 38: Customers & Distribution Channels

    37 Customers & Distribution Channels Therapy Hospital High Flow Therapy NIV Humidification & Masks Invasive Humidification Infant CPAP Infant Resuscitation > > Homecare High Flow Therapy Sleep Therapy NIV Humidification & Masks Invasive Humidification > Distribution Channel Distribution Partners F&P

  39. Slide 39: How does payment work?

    38 How does payment work? HOSPITAL Physician Distributors DRG - Diagnosis Related Groups Reimbursement tied to specific diagnosis during inpatient stay. HOMECARE Physician Reimbursement FFS - Fee for Service Reimbursement generally tied to specific product HCPC code for use in the home. Fisher & Pay

  40. Slide 40: Our People and Our Culture

    39 Our People and Our Culture North American engagement score Global top quartile for AON Hewitt surveyed companies We believe our people are our strength, and that an engaged workforce drives our success. We know it takes several years for a sales rep to become fully effective due to our long compl

  41. Slide 41: Questions?

    Quest Justin Callahan, President Fisher & Paykel Healthcare Inc. Fisheré.Paykel HEALTHCARE

  42. Slide 42: US Hospital Overview

    US Hospital Overview Steve Lacke, VP Sales & Marketing Steve Wilson, National Sales Manager Fisher & Paykel HEALTHCARE

  43. Slide 43: Our Route to Market

    Our Route to Market Fisher &.Paykel HEALTHCARE Group Purchasing Organizations Represent ~98% of US hospitals Combine the buying power of their members Negotiate standardized pricing and contract terms Fisher & Paykel HEALTHCARE

  44. Slide 44: GPO Process

    GPO Process + BEG MEMBERSHIP HOSPITAL GPO y, 43 NEGOTIATE: > PRICING Fisher& Paykel > CONTRACTS HEALTHCARE > FEES S Fisher& Paykel HEALTHCARE

  45. Slide 45: Estimated GPO Market Share

    44 Estimated GPO Market Share BVizient m Premier mw HealthTrust Intalere m@ Others MARKET SHARE Fisher & Paykel HEALTHCARE

  46. Slide 46: Integrated Delivery Networks (IDNs)

    45 Integrated Delivery Networks (IDNs) An IDN is a network of facilities that work together to offer a continuum of care to a specific geographic area or market Negotiate dollar and volume commitments with GPO contracted suppliers GPO Fisheré.Paykel HEALTHCARE

  47. Slide 47: Health of US Hospitals/Regulatory Environment

    46 Health of US Hospitals/Regulatory Environment Challenges Healthcare costs and spending exceed rates of inflation - Medicare Office of Actuary estimates healthcare spending will grow at an average rate of 5.8% from 2015 to 2025, 1.3% greater than the expected increase in GDP. Pricing pressure - CM

  48. Slide 48: Our Key Products in the Hospital

    47 Our Key Products in the Hospital Resuscitation Invasive Non-invasive ventilation ventilation Nasal high flow Fisheré.Paykel HEALTHCARE

  49. Slide 49: Optiflow Nasal High Flow Therapy

    Optiflow Nasal High Flow Therapy Optiflow Nasal High Flow therapy has been clinically proven to reduce the escalation of care when compared to other more conventional therapies (Oxygen Cannula, Oxygen Mask, NIV) Reducing the escalation of care within the acute care facility provides a positive impac

  50. Slide 50: For personal use only

    49 For personal use only • • • • − − −

  51. Slide 51: For personal use only

    50 For personal use only • • • • • •

  52. Slide 52: For personal use only

    51 For personal use only • • • • •

  53. Slide 53: Questions?

    Questions? Steve Lacke, VP Sales & Marketing Steve Wilson, National Sales Manager Fisher & Paykel HEALTHCARE

  54. Slide 54: Afternoon Break

    Ir personal use only Afternoon Break Fisher & Paykel

  55. Slide 55: Nasal High Flow Therapy: UCSD Perspective

    For personal use only Nasal High Flow Therapy: UCSD Perspective Timothy A. Morris, M.D. Professor of Medicine Division of Pulmonary and Critical Care Medicine Medical Director, Respiratory Care University of California, San Diego Disclosure: Timothy Morris, M.D. will be reimbursed by Fisher & Paykel

  56. Slide 56: UC San Diego Healthcare

    UC San Diego Healthcare For personal use only • UCSD Hillcrest Medical Center (390 beds) • Jacobs Medical Center (364 beds) • Sulpizio Cardiovascular Center (54 beds) • Average Daily Census: 504 • Annual Discharges: 29,200 • Average Length of Stay: 6.13 • Emergency Visits: 77,603 55

  57. Slide 57: My roles

    My roles For personal use only • Medical Director, Respiratory Care Department • Medical Director, Pulmonary Physiology Lab • Clinical Service Chief, Pulmonary and Critical Care • Critical care physician • Past-president, National Association for Medical Direction of Respiratory Care • President, Re

  58. Slide 58: Clinical niches at UCSD

    Clinical niches at UCSD For personal use only • Provide oxygen to alveoli 57

  59. Slide 59: Provision of oxygen

    Provision of oxygen For personal use only • FO2 of – 2 LPM NC – 6 LPM NC – 10 LPM face mask – 100% non-rebreather mask 58

  60. Slide 60: Inspiratory flow rates

    Inspiratory flow rates For personal use only 30 L/min 350 L/min 59

  61. Slide 61: Supplied vs entrained air

    Supplied vs entrained air For personal use only 2 LPM 100% O2 ??% O2 21% O2 Inspiratory flow 60

  62. Slide 62: Supplied vs entrained air

    Supplied vs entrained air For personal use only 6 LPM 100% O2 ??% O2 21% O2 Inspiratory flow 61

  63. Slide 63: Supplied vs entrained air

    Supplied vs entrained air For personal use only 60 LPM 100% O2 ??% O2 21% O2 Inspiratory flow 62

  64. Slide 64: Clinical niches at UCSD

    Clinical niches at UCSD For personal use only • Provide oxygen to alveoli – Pneumonia – Lung inflammation – Pneumothroax 63

  65. Slide 65: For personal use only

    UNIVERSITY of CALIFORNIA SAN DIEGO SCHOOL OF MEDICINE

  66. Slide 66: For personal use only

    UNIVERSITY of CALIFORNIA SAN DIEGO SCHOOL OF MEDICINE

  67. Slide 67: For personal use only

    e) UNIVERSITY of CALIFORNIA SAN DIEGO SCHOOL OF MEDICINE 66

  68. Slide 68: For personal use only

    fe) UNIVERSITY of CALIFORNIA SAN DIEGO SCHOOL OF MEDICINE

  69. Slide 69: Clinical niches at UCSD

    Clinical niches at UCSD For personal use only • Provide oxygen to alveoli • Provide water to airways 68

  70. Slide 70: Humidity

    69 For personal use only Humidity

  71. Slide 71: Jungle humidity

    70 For personal use only Jungle humidity

  72. Slide 72: Alveoli are 100% humid

    Alveoli are 100% humid at 37 C For personal use only 71

  73. Slide 73: Where does the water come from?

    Where does the water come from? For personal use only Alveolar air Ambient air this week 72

  74. Slide 74: Evaporation from airways

    Evaporation from airways For personal use only 73

  75. Slide 75: Mucociliary clearance

    Mucociliary clearance For personal use only 74

  76. Slide 76: Clinical niches at UCSD

    Clinical niches at UCSD For personal use only • Provide oxygen to alveoli • Provide water to airways – bronchiectasis – cystic fibrosis – chronic bronchitis – asthma – diffuse panbronchiolitis – plastic bronchitis – primary ciliary dyskinesia 75

  77. Slide 77: Clinical niches at UCSD

    Clinical niches at UCSD For personal use only • Provide oxygen to alveoli • Provide water to airways • Mechanical support to ventilation 76

  78. Slide 78: Increase the inspiratory support

    Increase the inspiratory support For personal use only Paw PEEP 77

  79. Slide 79: Clinical niches at UCSD

    Clinical niches at UCSD For personal use only • Provide oxygen to alveoli • Provide water to airways • Mechanical support to ventilation – Neuromuscular weakness – Rib fractures etc. 78

  80. Slide 80: Increase the PEEP

    Increase the PEEP For personal use only Paw PEEP 79

  81. Slide 81: Normal Alveoli

    80 For personal use only Normal Alveoli

  82. Slide 82: Emphysema

    81 For personal use only Emphysema

  83. Slide 83: Beginning of Exhalation

    Beginning of Exhalation For personal use only Normal Airway Obstruction 82

  84. Slide 84: End of Exhalation

    End of Exhalation For personal use only Normal Airway Obstruction 83

  85. Slide 85: Applied Pressure to Counter PEEPi

    Applied Pressure to Counter PEEPi For personal use only Airway Obstruction Applied Pressure 84

  86. Slide 86: Clinical niches at UCSD

    Clinical niches at UCSD For personal use only • Provide oxygen to alveoli • Provide water to airways • Mechanical support to ventilation – Neuromuscular weakness – Rib fractures etc. – COPD 85

  87. Slide 87: Clinical niches at UCSD

    Clinical niches at UCSD For personal use only • Provide oxygen to alveoli • Provide water to airways • Mechanical support to ventilation • Increase intrathoracic pressure 86

  88. Slide 88: For personal use only

    UNIVERSITY of CALIFORNIA C H F SAN DIEGO ‘SCHOOL OF MEDICINE 87

  89. Slide 89: CHF and positive intra-thoracic pressure

    CHF and positive intra-thoracic pressure For personal use only 88

  90. Slide 90: Positive intra-thoracic pressure during CHF

    Positive intra-thoracic pressure during CHF… For personal use only • decreases venous return • reduces right ventricle bulging into left ventricle • decreases left ventricle work 89

  91. Slide 91: Clinical niches at UCSD

    Clinical niches at UCSD For personal use only • Provide oxygen to alveoli • Provide water to airways • Mechanical support to ventilation • Increase intrathoracic pressure – Cardiomyopathy – Congestive heart failure 90

  92. Slide 92: Clinical niches at UCSD

    Clinical niches at UCSD For personal use only • Provide oxygen to alveoli Routine use • Provide water to airways Growing use • Mechanical support to ventilation Beginning use • Increase intrathoracic pressure Beginning use 91

  93. Slide 93: Thank you

    92 For personal use only Thank you

  94. Slide 94: US Homecare Overview

    US Homecare Overview Justin Callahan, President of US Operations Steve Polgar, VP Sales & Marketing ») Fisher & Paykel HEALTHCARE

  95. Slide 95: For personal use only

    94 For personal use only • • • • •

  96. Slide 96: Our Leading-Edge Masks

    95 Our Leading-Edge Masks oy Simplus” Eson"2 Brevida’ * Significant focus building awareness and confidence with sleep physicians Fisheré.Paykel HEALTHCARE

  97. Slide 97: Mask Matters Most Campaign

    For personal use only Mask Matters Most Campaign The Mask Matters Most’

  98. Slide 98: Rest. Assured.

    97 Rest. Assured. “My dad was always making things, fixing something for a neighbour, or building small yachts. He always encouraged me to think about how to improve and make iterations to designs, continuously improving and learning from previous mistakes. But more importantly to never give up and

  99. Slide 99: For personal use only

    98 For personal use only • − − − −

  100. Slide 100: For personal use only

    99 For personal use only • • • • −

  101. Slide 101: For personal use only

    100 For personal use only • • • • − − −

  102. Slide 102: For personal use only

    101 For personal use only • • • − − −

  103. Slide 103: Questions?

    Questions? Justin Callahan, President of US Operations Steve Polgar, VP Sales & Marketing a») Fisher & Paykel HEALTHCARE 2

  104. Slide 104: HCD COPD Program

    For personal use only HCD COPD Program The COPD Program offers comprehensive, personalized care for people with Chronic Obstructive Pulmonary Disease (COPD) John Olivas, President Rodolfo Blain, VP HME 103

  105. Slide 105: Disclosure

    Disclosure For personal use only John Olivas and Rodolfo Blain will be reimbursed by Fisher & Paykel Healthcare for any expenses incurred in connection with their participation in today’s event. 104

  106. Slide 106: Equipment for Improved Living

    Equipment for Improved Living For personal use only Durable Medical Equipment  Negative Pressure Wound Therapy  Feeding Pumps  Hospital Beds  Tens Units  Gel Mattresses  Incontinence Supplies  Low Air Loss Mattresses  Ventilators  Trapeze Bars  Oxygen Concentrators  Wheelchairs  O2 Conse

  107. Slide 107: COPD Program Goals

    COPD Program Goals For personal use only  Prevent disease progression  Relieve symptoms  Improve exercise tolerance  Improve health status  Prevent and treat complications  Prevent and treat exacerbations, reducing hospital admissions  Improve overall quality of life  People who learn about

  108. Slide 108: COPD Education

    COPD Education For personal use only  What is COPD  Respiratory System  What Happens to Your lungs with COPD  Medication Delivery Devices  Metered Dose Inhaler and Proper Use  Nebulizer and Proper Use  Albuterol  Home Oxygen  When to call your Primary Care Physician 107

  109. Slide 109: Standard COPD Program Length

    Standard COPD Program Length For personal use only The standard COPD program stay will last 5 weeks with an extra 1 week to be reserved for as needed (PRN). The first week will run Monday through Friday with scheduled 1 hour daily sessions as follows:  Week 1, Monday through Friday with scheduled 1

  110. Slide 110: COPD Program and Airvo

    COPD Program and Airvo For personal use only INDICATION FOR AIRVO 2 HIGH FLOW HUMIDIFICATION  Reoccurring Hospitalizations due to COPD exacerbation (Yellow Zone)  Potential for/or Presence of Atelectasis  Bronchospasm  Bronchiectasis  Need for Hydration and of Retained Secretions  Need for Hea

  111. Slide 111: Airvo Case

    Airvo Case 1 For personal use only  70 y/o Hispanic female presented with diagnosis of COPD  3 prior hospitalizations last one 04/03/18  Admitted into COPD program on 05/16/18 w/Airvo  Followed for the initial four week COPD program visits in which her vital signs remained within normal limits,

  112. Slide 112: Airvo Case

    Airvo Case 2 For personal use only  83 y/o Hispanic male presented with diagnosis of COPD  Multiple hospitalizations for exacerbation of his COPD  Most resent hospitalization was in 06/17/18 for 10 days  Admitted post hospitalization 06/28/18  His bilateral breath sounds were with rhonchi to up

  113. Slide 113: Airvo Case

    Airvo Case 3 For personal use only  66 y/o Hispanic male presented with diagnosis of COPD  Two prior hospitalizations for COPD exacerbation  admitted into COPD program on 07/18/18  patient completed the COPD program with unremarkable results and no visits to the ER and no hospitalizations. 112

  114. Slide 114: Lewis Gradon

    Lewis Gradon Fisher & Paykel HEALTHCARE

Fisher & Paykel Healthcare — Investor Day (September 2018) on 6ix